1. Home
  2. VYNE vs DEVS Comparison

VYNE vs DEVS Comparison

Compare VYNE & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • DEVS
  • Stock Information
  • Founded
  • VYNE 2003
  • DEVS N/A
  • Country
  • VYNE United States
  • DEVS Canada
  • Employees
  • VYNE N/A
  • DEVS N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • DEVS
  • Sector
  • VYNE Health Care
  • DEVS
  • Exchange
  • VYNE Nasdaq
  • DEVS NYSE
  • Market Cap
  • VYNE 16.0M
  • DEVS 14.6M
  • IPO Year
  • VYNE 2018
  • DEVS N/A
  • Fundamental
  • Price
  • VYNE $1.45
  • DEVS $0.36
  • Analyst Decision
  • VYNE Strong Buy
  • DEVS
  • Analyst Count
  • VYNE 2
  • DEVS 0
  • Target Price
  • VYNE $6.25
  • DEVS N/A
  • AVG Volume (30 Days)
  • VYNE 1.3M
  • DEVS 1.0M
  • Earning Date
  • VYNE 08-13-2025
  • DEVS 07-15-2025
  • Dividend Yield
  • VYNE N/A
  • DEVS N/A
  • EPS Growth
  • VYNE N/A
  • DEVS N/A
  • EPS
  • VYNE N/A
  • DEVS N/A
  • Revenue
  • VYNE $605,000.00
  • DEVS $10,164.00
  • Revenue This Year
  • VYNE $42.51
  • DEVS N/A
  • Revenue Next Year
  • VYNE N/A
  • DEVS N/A
  • P/E Ratio
  • VYNE N/A
  • DEVS N/A
  • Revenue Growth
  • VYNE 43.03
  • DEVS N/A
  • 52 Week Low
  • VYNE $0.85
  • DEVS $0.18
  • 52 Week High
  • VYNE $4.30
  • DEVS $3.00
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 56.76
  • DEVS N/A
  • Support Level
  • VYNE $0.85
  • DEVS N/A
  • Resistance Level
  • VYNE $1.96
  • DEVS N/A
  • Average True Range (ATR)
  • VYNE 0.20
  • DEVS 0.00
  • MACD
  • VYNE 0.07
  • DEVS 0.00
  • Stochastic Oscillator
  • VYNE 51.80
  • DEVS 0.00

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Share on Social Networks: